159 related articles for article (PubMed ID: 12107937)
21. From observational studies to randomized trials: asking the right question at the right time.
Neaton JD; Mugglin AS
J Clin Periodontol; 2006 Aug; 33(8):517-9. PubMed ID: 16899092
[No Abstract] [Full Text] [Related]
22. Examining heterogeneity in phase II trial designs may improve success in phase III.
Tuma RS
J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
[No Abstract] [Full Text] [Related]
23. Defining the role of raloxifene for the prevention of breast cancer.
Kalidas M; Hilsenbeck S; Brown P
J Natl Cancer Inst; 2004 Dec; 96(23):1731-3. PubMed ID: 15572750
[No Abstract] [Full Text] [Related]
24. Confounding: regression adjustment.
Fitzmaurice G
Nutrition; 2006 May; 22(5):581-3. PubMed ID: 16600821
[No Abstract] [Full Text] [Related]
25. Dropouts and missing data in psychiatric clinical trials.
Potkin SG; Siu CO
Am J Psychiatry; 2009 Nov; 166(11):1295; author reply 1295-6. PubMed ID: 19884237
[No Abstract] [Full Text] [Related]
26. Postmastectomy radiotherapy: quality counts!
Prosnitz LR; Marks LB
J Natl Cancer Inst; 2006 Jan; 98(1):3-4. PubMed ID: 16391361
[No Abstract] [Full Text] [Related]
27. Multiple logistic regression models--what are they?
Campbell M
Midwifery; 2004 Sep; 20(3):236-9. PubMed ID: 15337279
[No Abstract] [Full Text] [Related]
28. The statistician and the data monitoring committee.
D'Agostino RB
Stat Med; 2004 May; 23(10):1501-2. PubMed ID: 15122726
[No Abstract] [Full Text] [Related]
29. The World Cancer Research Fund Expert Report: the next steps.
Wiseman MJ
IARC Sci Publ; 2002; 156():523-4. PubMed ID: 12484250
[No Abstract] [Full Text] [Related]
30. Dose density in breast cancer: a simple message?
Lin NU; Gelman R; Winer EP
J Natl Cancer Inst; 2005 Dec; 97(23):1712-4. PubMed ID: 16333021
[No Abstract] [Full Text] [Related]
31. Re: "Variable selection for propensity score models".
Shrier I; Platt RW; Steele RJ
Am J Epidemiol; 2007 Jul; 166(2):238-9. PubMed ID: 17526863
[No Abstract] [Full Text] [Related]
32. Can exercise prevent the common cold?
Ruffin R; Thompson PD
Am J Med; 2006 Nov; 119(11):909. PubMed ID: 17071152
[No Abstract] [Full Text] [Related]
33. Cohort studies: marching forward.
Thadhani R; Tonelli M
Clin J Am Soc Nephrol; 2006 Sep; 1(5):1117-23. PubMed ID: 17699334
[No Abstract] [Full Text] [Related]
34. Mortality and poststroke depression.
Sonis J
Am J Psychiatry; 2004 Aug; 161(8):1506-7; author reply 1507-8. PubMed ID: 15285995
[No Abstract] [Full Text] [Related]
35. Quantitative assessment of unobserved confounding is mandatory in nonrandomized intervention studies.
Groenwold RH; Hak E; Hoes AW
J Clin Epidemiol; 2009 Jan; 62(1):22-8. PubMed ID: 18619797
[TBL] [Abstract][Full Text] [Related]
36. The architecture of scientific research.
Ostelo RW; de Vet HC; van Beek HJ
Aust J Physiother; 2004; 50(3):189-92. PubMed ID: 15490525
[No Abstract] [Full Text] [Related]
37. Re: Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles.
Pereira C; Castilho E
Am J Epidemiol; 2009 Mar; 169(6):783; author reply 783-4. PubMed ID: 19208724
[No Abstract] [Full Text] [Related]
38. [The concordance test between two experts].
Dupuy A; Guillaume JC
Ann Dermatol Venereol; 2003 May; 130(5):570. PubMed ID: 12843842
[No Abstract] [Full Text] [Related]
39. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making.
Etminan M; Gill S; Fitzgerald M; Samii A
J Clin Pharmacol; 2006 Jan; 46(1):6-9. PubMed ID: 16397278
[TBL] [Abstract][Full Text] [Related]
40. Estimating the impact of the discontinuation of medical interventions on health outcomes.
Weiss NS
Am J Epidemiol; 2009 Mar; 169(6):653-6. PubMed ID: 19126592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
